13F-HR filed by Darwin Global Management, Ltd.
Darwin Global Management, Ltd. filed this 13F-HR for the quarter ended 2024-06-30, filed 2024-08-14, with 9 holding rows worth $859,473,928.
- Accession
- 0001892688-24-000095
- Filer
- CIK 1839209
- Filed
- 2024-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2024
A holdings report, 9 entries on the cover page, a total value of $859,473,928 stated on the cover page (in dollars after the unit check, H1), rows summing to $859,473,928 with VALUE read as dollars as filed, 13F file number 028-21006. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CYTOKINETICS INC | 23282W605 | COM NEW | 4,575,558 | $246,073,509 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 3,541,095 | $237,076,310 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 2,080,946 | $163,916,116 | dollars as filed | |
| GERON CORP | 374163103 | COM | 23,915,480 | $106,184,731 | dollars as filed | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 1,525,902 | $68,772,403 | dollars as filed | |
| CORBUS PHARMACEUTICALS | 21833P301 | COM NEW | 325,140 | $14,267,143 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 452,040 | $10,265,828 | dollars as filed | |
| AVIDITY BIOSCIENCES INC COM | 05370A108 | Stock | 200,000 | $8,108,000 | dollars as filed | |
| ELEVATION ONCOLOGY INC COM | 28623U101 | Stock | 1,916,290 | $4,809,888 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001892688-24-000095 | this filing | 2024-08-14 | acceptance time not in the bulk data set |